💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Advanced Enzyme Technologies Limited is an India-based company engaged in the manufacturing of enzymes and probiotics. It is focused on the research and development, manufacturing, and marketing of approximately 400 products, developed from over 68 enzymes and probiotics. It…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A high-quality, steadily growing business, trading cheap versus its own history.
Advanced Enzyme Tech is scored on the pharma / healthcare framework. It keeps a fat 22.2% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 0.90×). Free cash flow is worth about 2.7% of its market value.
Over the last 3 years revenue compounded at 11%/yr and profit at 19%/yr. Book value has grown 9%/yr. Return on equity is a modest 10.3%. In the latest quarter profit grew 33% versus the prior quarter.
At 19× earnings, the stock sits at the 4th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~7%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 17.23 | — | — |
| P/B | 1.84 | 4.1 | better |
| EV/EBITDA | 10.73 | 19.33 | better |
| ROE | 10.26 | — | — |
| ROCE | 14.16 | 14.41 | worse |
| ROA | 9.35 | 1.64 | better |
| Quick Ratio | 8.12 | 4.8 | better |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Revenue has grown every year across all 4 financial years shown. 11% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Profit is growing faster than revenue (19% vs 11%) — margin expansion is at work.
Operating margin has expanded from 25% to 30% — the business is keeping more of each rupee earned.
ROE at 10% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
17% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Heavy investing spend every year, but operations generate enough to cover it — the business self-funds its growth. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue rose 10% sequentially — momentum is building. Run-rate stepping up — recent quarters average 9% above earlier ones.
Profit jumped 33% QoQ — check if this is operating leverage or a one-off item.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 43.6% — dispersed ownership; institutional flows drive the stock.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.